Document:

EX-10.1 Form of Restricted Unit Certificate

Exhibit 10.1

KING PHARMACEUTICALS, INC.

INCENTIVE PLAN

RESTRICTED UNIT CERTIFICATE

     This Certificate, when executed by a duly authorized officer of King Pharmaceuticals, Inc.
(the “Company”), evidences the grant by the Company to the Participant named below of Restricted
Units of the Company.

	 	 	 
	1. Name of Participant:
	 	 
	 

	 	 
	2. Social Security Number of Participant:
	 	 
	 

	 	 
	3. Date of Grant:
	 	 
	 

	 	 
	4. Type of Grant:
	 	 
	 

	 	 
	5. Number of Shares:
	 
	 

	 	 

This Restricted Unit grant is subject to and governed by the terms of this Restricted Unit
Certificate, the Restricted Unit Settlement Election Form (attached hereto and incorporated by
reference herein), the Restricted Unit Grant Agreement (attached hereto and incorporated by
reference herein) and the Company’s Incentive Plan.

	 	 	 	 	 
	 	KING PHARMACEUTICALS, INC.,

 	 
	 	By:  	 	 
	 	 	Name:  	Brian A. Markison 	 
	 	 	Title:  	President and Chief Executive Officer 	 

 

 

	 	 	 	 	 

RESTRICTED UNIT SETTLEMENT ELECTION FORM

RELATING TO

KING PHARMACEUTICALS, INC. RESTRICTED UNITS

You have been granted an award of Restricted Units of King Pharmaceuticals, Inc. (the “Company”)
pursuant to the Company’s Incentive Plan (the “Plan”) as set forth in the Restricted Unit
Certificate, dated as of [DATE OF GRANT] (the “Grant Date”), to which this Restricted Unit
Settlement Election Form (this “Election Form”) is attached. In order to allow you the opportunity
to defer taxation of the shares of Common Stock (as defined in the Plan) subject to the Restricted
Units until you cease to be a Non-Employee Director (as defined in the Plan) of the Company and you
are no longer subject to the restrictions on sales of shares that apply to Non-Employee Directors,
you are being offered a one-time opportunity to elect to defer the delivery of those shares, as
described in this Election Form and the Restricted Unit Grant Agreement. Any election that you
make pursuant to this Election Form will apply to 100% of the Restricted Units.

In order to make your election, please check the appropriate box below and return a signed
copy of this Election Form to the Company not later than 5:00 p.m. EST on the 20th business day
following the Grant Date, as set forth in the Restricted Unit Certificate. If you do not return a
signed copy of this Election Form to the Company by 5:00 p.m. EST on the 20th business day
following the Grant Date, you will be deemed to have elected Alternative One below.

	 	 	 
	~

	 	Alternative One — I would like to receive the shares of Common Stock
with respect to my Restricted Units on the first anniversary of the Grant Date in
accordance with Section 3(a) of the Restricted Unit Grant Agreement, unless they are
delivered prior to that date as set forth in Section 3(b), (c) or (d) of the
Restricted Unit Grant Agreement. I understand that by electing this alternative, I am
agreeing that my Restricted Units will be forfeited if I cease to be a Non-Employee
Director of the Company for any reason prior to the first anniversary of the Grant
Date, other than due to death, Disability (as defined in the Plan) or a Term
Completion Event (as defined in Section 3(b) of the Restricted Unit Grant Agreement).
	 
	 	 
	or
	 	 
	 
	 	 
	~

	 	Alternative Two — I would like to defer the receipt of the shares of
Common Stock with respect to my Restricted Units until six months after I cease to be
a Non-Employee Director of the Company as set forth in Section 4(a), unless they are
delivered prior to that date as set forth in Section 4(b) or (c) of the Restricted
Unit Grant Agreement. I understand that the forfeiture conditions that would apply to
my Restricted Units pursuant to Alternative One will not apply if I select this
alternative, and that my Restricted Units will not be forfeited following the Grant
Date, unless I cease to be a Non-Employee Director of the Company as a result of
termination of my service for Cause (as defined in the Plan and as provided in Section
4(d)).

2

 

Acknowledgments — I have read this Election Form, and I understand that once I have
submitted this Election Form to the Company, my election with respect to the Restricted Units will
be irrevocable and I will not be able to change it for any reason. I have been afforded adequate
time to review this Election Form and to consult with the advisor or attorney of my choice, and I
fully understand the terms and conditions of my election.

_______________________

Name:

After signing this election form, please fax it to the Company at [FAX NUMBER], attention General
Counsel, on or before [INSERT DATE] at 5:00 p.m. EST. Please retain a copy for your records.

3

 

RESTRICTED UNIT GRANT AGREEMENT

PURSUANT TO THE KING PHARMACEUTICALS, INC.

INCENTIVE PLAN

     This Restricted Unit Grant Agreement (the “Agreement”) is made as of the date set forth on the
Restricted Unit Certificate to which this Agreement is attached (the “Grant Date”) by King
Pharmaceuticals, Inc. (the “Company”) and the individual identified on the Restricted Unit
Certificate (the “Participant”) to effect an award of restricted units by the Company to the
Participant on the terms and conditions set forth below:

     1. AWARD OF RESTRICTED UNITS.

     As of the Grant Date, subject to the terms, conditions and restrictions set forth herein, the
Company grants and issues to the Participant units representing a contingent entitlement of the
Participant to receive the number of shares of Common Stock indicated on the Restricted Unit
Certificate at the time specified in this Agreement, provided the Participant satisfies the
requirements of this Agreement (the “Restricted Units”). The Restricted Units are subject to the
Restricted Unit Settlement Election Form (the “Election Form”) provided to the Participant together
with this Agreement. Pursuant to the Election Form, the Participant was given the opportunity to
elect Alternative One or Alternative Two. If the Participant elects Alternative One (or is deemed
to have elected Alternative One because the Participant does not return the Election Form to the
Company), the settlement of the Participant’s Restricted Units will be governed by Section 3 of
this Agreement. If the Participant elects Alternative Two, the settlement of the Participant’s
Restricted Units will be governed by Section 4 of this Agreement.

     2. GOVERNING PLAN.

     The Restricted Units shall be granted pursuant to and (except as specifically set forth
herein) subject in all respects to the applicable provisions of the King Pharmaceuticals, Inc.
Incentive Plan (“Plan”), which are incorporated herein by reference. Terms not otherwise defined in
this Agreement have the meanings ascribed to them in the Plan.

     3. SETTLEMENT OF RESTRICTED UNITS UNDER ALTERNATIVE ONE.

(a) Settlement on First Anniversary of Grant Date. On the first anniversary of
the Grant Date, the Participant will be entitled to receive the number of shares of
Common Stock as is set forth on the Restricted Unit Certificate, provided that the
Participant continues to be a Non-Employee Director of the Company as of such date.

(b) Settlement Following a Term Completion Event. If, prior to the first
anniversary of the Grant Date, the Participant ceases to be a Non-Employee Director of
the Company as a result of a Term Completion Event (as defined below), then the
Participant will be entitled to receive the number of shares of Common Stock as is set
forth on the Restricted Unit Certificate on the earlier of (i) the first anniversary of
the Grant Date and (ii) the later of (A) the six-month anniversary of the Term
Completion Event and (B) January 1, 2009. For purposes of this Agreement, a “Term
Completion Event” shall mean any of the following: (1) the Participant, standing for
reelection, is not reelected; (2) the Participant completes his or her term of office
after declining to stand for reelection; (3) the Participant completes his or her term
of office after not

4

 

being nominated to stand for reelection; or (4) the Participant completes his or her
term of office, having been ineligible to stand for reelection under term limit
provisions then in effect.

(c) Settlement Following Death or Disability. If, prior to the first
anniversary of the Grant Date, the Participant ceases to be a Non-Employee Director of
the Company as a result of death or Disability (as defined in clause (b) of the
definition set forth in the Plan), then the Participant will be entitled to receive the
number of shares of Common Stock as is set forth on the Restricted Unit Certificate on
the later of (i) the date that the Participant’s service terminates as a result of death
or Disability and (ii) January 1, 2009.

(d) Settlement Following a Change of Control. If a Change of Control occurs
prior to the first anniversary of the Grant Date, then provided that the Participant has
not forfeited the RSUs pursuant to Section 3(e) below, the Participant will be entitled
to receive the number of shares of Common Stock as is set forth on the Restricted Unit
Certificate on the later of (i) the date that the Change of Control occurs and (ii)
January 1, 2009.

(e) Forfeiture. If, prior to the first anniversary of the Grant Date, the
Participant ceases to be a Non-Employee Director of the Company for any reason other
than death, Disability or a Term Completion Event, then as of the date on which the
Participant ceases to be a Non-Employee Director, the Restricted Units shall immediately
be forfeited and the Participant shall have no rights to receive any payout under this
Agreement.

     4. SETTLEMENT OF RESTRICTED UNITS UNDER ALTERNATIVE TWO.

(a) Settlement Following a Term Completion Event. If, at any time following the
Grant Date, the Participant ceases to be a Non-Employee Director of the Company for any
reason other than as a result of termination of the Participant’s service for Cause,
then the Participant will be entitled to receive the number of shares of Common Stock as
is set forth on the Restricted Unit Certificate on later of (i) the six-month
anniversary of the Term Completion Event and (ii) January 1, 2009.

(b) Settlement Following Death or Disability. If, at any time following the
Grant Date, the Participant ceases to be a Non-Employee Director of the Company as a
result of death or Disability, then the Participant will be entitled to receive the
number of shares of Common Stock as is set forth on the Restricted Unit Certificate on
the later of (i) the date that the Participant’s service terminates as a result of death
or Disability and (ii) January 1, 2009.

(c) Settlement Following a Change of Control. If a Change of Control occurs at
any time following the Grant Date, then provided that the Participant has not forfeited
the RSUs pursuant to Section 4(d) below, the Participant will be entitled to receive
the number of shares of Common Stock as is set forth on the Restricted Unit Certificate
on the later of (i) the date that the Change of Control occurs and (ii) January 1, 2009.

(d) Forfeiture. If, at any time following the Grant Date, the Participant
ceases to be a Non-Employee Director of the Company as a result of termination of the
Participant’s

5

 

service for Cause, then as of the date on which the Participant ceases to be a
Non-Employee Director, the Restricted Units shall immediately be forfeited and the
Participant shall have no rights to receive any payout under this Agreement.

     5. FORM AND TIMING OF PAYMENT.

     All payments of Restricted Units pursuant to this Agreement will be made in the form of shares
of Common Stock. Except as otherwise provided in this Agreement, any payment that becomes due
pursuant to this Agreement will be made within 60 days of the date on which the Participant becomes
entitled to payment in accordance with Section 3 or Section 4, as applicable.

     6. VOTING AND DIVIDEND RIGHTS.

     The Participant shall have no rights as a shareholder, including voting and dividend rights,
with respect to the Restricted Units. The Participant will obtain full voting and other rights as a
shareholder of the Company upon a payment in shares of Common Stock, as provided in Section 5
above.

     7. ADDITIONAL AGREEMENTS.

(a) Tax Matters. The Restricted Units granted are subject to appropriate income
tax withholding and other deductions required by applicable laws or regulations, and
Participant and his successors will be responsible for all income and other taxes
payable as a result of a payout under the Restricted Units or otherwise in connection
with this Agreement. The Company will have the power and the right to deduct or
withhold, or require the Participant or the Participant’s beneficiary to remit to the
Company, the minimum necessary amount to satisfy federal, state, and local taxes,
domestic or foreign, required by law or regulation to be withheld with respect to any
taxable event arising as a result of this Agreement. The Company is not required to
provide any gross-up or other tax assistance.

(b) Independent Advice; No Representations. Participant acknowledges that (i)
(s)he was free to use professional advisors of his choice in connection with this
Agreement, has received advice from her/his professional advisors in connection with
this Agreement, understands its meaning and import, and is entering into this Agreement
freely and without coercion or duress; and (ii) (s)he has not received and is not
relying upon any advice, representations or assurances made by or on behalf of the
Company or any Company affiliate or any employee of or counsel to the Company regarding
any tax or other effects or implications of the Restricted Units or other matters
contemplated by this Agreement.

(c) Value of Restricted Units. No representations or promises are made to
Participant regarding the value of the Restricted Units or Company’s business prospects.
Participant acknowledges that information about investment in Company stock, including
financial information and related risks, is contained in Company’s SEC reports which
have been made available for Participant’s review at any time before Participant’s
acceptance of this Agreement. Further, Participant understands that the Company does not
provide tax or investment advice and acknowledges Company’s

6

 

recommendation that Participant consult with independent specialists regarding such
matters. Sale or other transfer of the Company stock may be limited by and subject to
Company policies as well as applicable securities laws and regulations.

(d) Adjustment in Capitalization. In the event of an Adjustment Event that is a
merger, consolidation, reorganization, liquidation, dissolution or other similar
transaction, then the Award pursuant to Section 1 of this Agreement shall be deemed to
pertain to the securities and other property, including cash, to which a holder of the
number of shares equal to the number of Restricted Units would have been entitled to
receive in connection with such Adjustment Event.

     8. SECTION 409A OF THE INTERNAL REVENUE CODE.

(a) It is intended that the provisions of this Agreement comply with Section 409A of the
Code (“Section 409A”), and all provisions of this Agreement shall be construed and
interpreted in a manner consistent with the requirements for avoiding taxes and
penalties under Section 409A.

(b) Neither the Participant nor any of the Participant’s creditors or beneficiaries
shall have the right to subject any deferred compensation (within the meaning of Section
409A) payable under this Agreement to any anticipation, alienation, sale, transfer,
assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under
Section 409A, any deferred compensation (within the meaning of Section 409A) payable to
the Participant or for the Participant’s benefit under this Agreement may not be reduced
by, or offset against, any amount owing by the Participant to the Company or any of its
Subsidiaries. Notwithstanding any provision set forth in this Agreement regarding the
timing of payment, in no event will the Participant have the right to designate the
taxable year of any payment.

(c) In no event will the Participant be entitled to payment with respect to the
Restricted Units pursuant to Section 3(b) or 4(a) unless the Participant has experienced
a “separation from service” within the meaning of Section 409A. Moreover, in no event
will the Participant be entitled to payment with respect to the Restricted Units
pursuant to Section 3(d) or 4(c) unless a Change of Control (as defined in the Plan)
that qualifies as an event described in Section 409A(a)(2)(A)(v) of the Code has
occurred.

(d) Notwithstanding any provision of this Agreement to the contrary, in light of the
uncertainty with respect to the proper application of Section 409A, the Company reserves
the right to make amendments to this Agreement as the Company deems necessary or
desirable to avoid the imposition of taxes or penalties under Section 409A. In any
case, the Participant shall be solely responsible and liable for the satisfaction of all
taxes and penalties that may be imposed the Participant or for the Participant’s account
in connection with this Agreement (including any taxes and penalties under Section
409A), and neither the Company nor any of its Subsidiaries shall have any obligation to
indemnify or otherwise hold the Participant harmless from any or all of such taxes or
penalties.

7

 

     9. GENERAL.

(a) Successors and Assigns. This Agreement is personal in its nature and
Participant may not assign or transfer his/her rights under this Agreement.

(b) Notices. Any notices, demands or other communications required or desired to
be given by any party shall be in writing and shall be validly given to another party if
served either personally or if deposited in the United States mail, certified or
registered, postage prepaid, return receipt requested. If such notice, demand or other
communication shall be served personally, service shall be conclusively deemed made at
the time of such personal service. If such notice, demand or other communication is
given by mail, such notice shall be conclusively deemed given forty-eight (48) hours
after the deposit thereof in the United States mail addressed to the party to whom such
notice, demand or other communication is to be given as hereinafter set forth:

	 	 	 
	To the Company:

	 	King Pharmaceuticals, Inc.
	 

	 	501 Fifth Street
	 

	 	Bristol, TN 37620
	 

	 	Attention: General Counsel

     To Participant: At his/her address of record as maintained in the Company’s files.

Any party may change its address for the purpose of receiving notices, demands and other
communications by providing written notice to the other party in the manner described in this
paragraph.

(c) Entire Agreement. Except as this Agreement may expressly provide otherwise,
this Agreement, the Restricted Unit Certificate, the Election Form and the Plan
constitute the entire agreement and understanding of the Company and Participant with
respect to the subject matter hereof and thereof, and supersede all prior written or
verbal agreements and understandings between Participant and the Company relating to
such subject matter.

(d) Governing Law; Severability. This Agreement will be construed and
interpreted under the laws of the State of Tennessee applicable to agreements executed
and to be wholly performed within the State of Tennessee. If any provision of this
Agreement as applied to any party or to any circumstance is adjudged by a court of
competent jurisdiction to be void or unenforceable for any reason, the invalidity of
that provision shall in no way affect (to the maximum extent permissible by law) the
application of such provision under circumstances different from those adjudicated by
the court, the application of any other provision of this Agreement, or the
enforceability or invalidity of this Agreement as a whole. If any provision of this
Agreement becomes or is deemed invalid, illegal or unenforceable in any jurisdiction by
reason of the scope, extent or duration of its coverage, then such provision shall be
deemed amended to the extent necessary to conform to applicable law so as to be valid
and enforceable or, if such provision cannot be so amended without materially altering
the intention of the parties, then such provision will be stricken and the remainder of
this Agreement shall continue in full force and effect.

(e) Remedies. All rights and remedies provided pursuant to this Agreement or by
law shall be cumulative, and no such right or remedy shall be exclusive of any other. A
party may pursue any one or more rights or remedies hereunder or may seek damages

8

 

or specific performance in the event of another party’s breach hereunder or may pursue
any other remedy by law or equity, whether or not stated in this Agreement.

(f) Interpretation. Headings herein are for convenience of reference only, do
not constitute a part of this Agreement, and will not affect the meaning or
interpretation of this Agreement. References herein to Sections are references to the
referenced Section hereof, unless otherwise specified.

(g) Waivers; Amendments. The waiver by either party of a breach of any provision
of this Agreement shall not operate or be construed as a waiver of any later breach of
that provision. This Agreement may be modified only by written agreement signed by
Participant and an authorized officer of the Company.

9EX-10.3.1

EXHIBIT 10.3.1

* Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment

which has been filed separately with the SEC.

SECOND AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT

FOR N-ACETYLCYSTEINE

     THIS SECOND AMENDMENT (the “Second Amendment”) to that certain Manufacturing and
Supply Agreement for N-Acetylcysteine, dated as of January 15, 2002 (the “Original
Agreement”), as modified by that certain Novation Agreement, dated as of January 27, 2006 (the
“Novation Agreement”), and as amended by that certain First Amendment to Manufacturing and
Supply Agreement for N-Acetylcyesteine dated as of November 16, 2006 (the “First
Amendment”) is entered into by and between CUMBERLAND PHARMACEUTICALS INC., a corporation
organized and existing under the laws of Tennessee, United States (“CUMBERLAND”), and
BIONICHE TEORANTA, a corporation organized and existing under the laws of Ireland
(“BIONICHE”), and is effective as of March 25, 2008 (The Original Agreement, the Novation
Agreement, and the First Amendment are collectively referred to herein as the “Agreement”).
Capitalized terms used but not defined in this Second Amendment shall have the meanings that are
set forth in the Agreement.

WITNESSETH:

     WHEREAS, BIONICHE is the assignee under the Agreement of BIONICHE PHARMA GROUP LIMITED, an
Affiliate thereof.

     NOW, THEREFORE, in consideration of the mutual covenants, agreements, representation and
warranties contained herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:

	 	1.	 	Paragraph 1.18 defines TERRITORY as having the meaning set
forth in Schedule III. Schedule III of the Agreement, and therefore the
TERRITORY, is hereby amended and restated as follows:
	 
	 	 	 	The United States of America, Australia, New Zealand, Singapore, Malaysia,
Hong Kong, China, Vietnam, Thailand, Taiwan, Korea, the Philippines and each
of their territories and possessions on the Effective Date of this Second
Amendment.
	 
	 	2.	 	Paragraph 5.6 is hereby amended by adding clause (d) as
follows:

(d) Notwithstanding the foregoing, CUMBERLAND may establish a
secondary supply arrangement with a third party. For Drug Product manufactured
by a third party supplier for commercial sale by CUMBERLAND during the term of
the Original Agreement, CUMBERLAND will pay BIONICHE at a rate of [***] CDN
for each 30 mL vial of the Drug Product that CUMBERLAND purchases from such
third party. Payment will be made by CUMBERLAND to BIONICHE within [***] days
after the Drug Product is delivered by the third party and released for sale by
CUMBERLAND.

 

 

	 	3.	 	The following is hereby added to the end of Paragraph 2.7 of the existing
Agreement:
	 
	 	 	 	In the event that CUMBERLAND arranges to sell Drug Product or have Drug
Product sold in a region or market whose regulatory authority requires a
unique label; or if CUMBERLAND contracts a third party to sell Drug Product,
and this third party requires a unique label, then BIONICHE shall divide the
Labeling of Drug Product in the applicable Purchase Order between the unique
label and the usual and customary CUMBERLAND label in accordance with
CUMBERLAND’s request. In such an event, CUMBERLAND will provide such unique
label to BIONICHE and clearly identify the division of Drug Product between
the two labels on any applicable Purchase Order.
	 
	 	 	 	Upon request by CUMBERLAND, BIONICHE will ship a whole or partial Order of the
Drug Product to fulfill the commitments in a given region or market directly
to a secondary distributor or to a third party or its identified distributor.
In such an event, CUMBERLAND will identify on the applicable Purchase Order
the requested shipment destination and any shipping instructions.

	 	4.	 	In the section entitled “Pricing” in SCHEDULE I, the first
paragraph is hereby amended and restated as follows:
	 
	 	 	 	Pursuant to Paragraph 2.10(a) of the Original Agreement, the price to be paid
by CUMBERLAND to BIONICHE in the year 2008 for the Drug Products ordered from
BIONICHE is as follows:

N-acetylcysteine 30 mL            Canadian            $[***]

Any price adjustment after 2008 shall be made in accordance with Paragraph
2.10(b)

	 	5.	 	In the section entitled “Pricing” in SCHEDULE I, the first
sentence of the fourth paragraph is hereby amended and restated as follows:
	 
	 	 	 	In addition, CUMBERLAND shall pay to BIONICHE a royalty equal to [***] percent
([***]%) of Net Sales (as defined herein) during each calendar year through
December 31, 2010, and during the period thereafter ending January 23, 2011 on
product manufactured by BIONICHE or by a 3rd party contractor for
CUMBERLAND provided that CUMBERLAND shall pay BIONICHE such royalty on a
quarterly basis within [***] days after the last day of the applicable
calendar quarter.

2

 

	 	6.	 	Miscellaneous.

(a) Authorization. Each party to this Second Amendment hereby
represents and warrants that the execution, delivery and performance of this
Second Amendment is within the powers of such party and has been duly
authorized by the party, is in accordance with all applicable laws and
regulations, and this Second Amendment constitutes the valid and enforceable
obligation of each party in accordance with its terms.

(b) Effect of Second Amendment. Each party acknowledges that this
Second Amendment constitutes a written instrument as contemplated by Paragraph
11.2 of the Agreement. Except as specifically amended above, the Agreement
shall remain in full force and effect, and is hereby ratified and confirmed.

(c) Counterparts. This Second Amendment may be executed in any number
of counterparts, each of which may be executed by only one of the parties
hereto, and each of which shall be enforceable against the party actually
executing such counterpart, and all of which shall together constitute one
instrument.

(d) Titles and Subtitles. The titles and subtitles used in this
Second Amendment are used for convenience only and are not to be considered in
construing or interpreting this Second Amendment.

(e) Governing Law and Dispute Resolution. This Second Amendment shall
be construed in accordance with the laws of the State of New York without
regard to applicable conflicts of laws provisions and any dispute,
controversy, or claim arising out of or relating to this Second Amendment
shall be governed by the provisions of Paragraph 11.7 of the Agreement.

(f) Severability. Should any part of this Second Amendment be invalid
or unenforceable, such invalidity or unenforceability shall not affect the
validity and enforceability of the remaining portion.

3

 

IN WITNESS WHEREOF, each of the undersigned has caused this Second Amendment to be effective as of
the date first above written.

	 	 	 	 	 
	 	CUMBERLAND:

CUMBERLAND PHARMACEUTICALS INC.

 	 
	 	By:  	/s/ A.J. Kazimi
 	 
	 	 	Name:  	A. J. Kazimi 	 
	 	 	Title:  	Chief Executive Officer 	 
	 

Date: March 25, 2008

	 	 	 	 	 
	 	BIONICHE:

BIONICHE TEORANTA

 	 
	 	By:  	/s/ George Zorich
 	 
	 	 	Name:  	George S Zorich 	 
	 	 	Title:  	President, North American Operations 	 
	 

Date: April 1, 2008

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]